ACTL6A

Across TCGA pan-cancer cohorts, ACTL6A RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated ACTL6A data layer compared with 2 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ACTL6A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTL6A expression acts as an unfavorable survival marker, although some lineages such as KIRC and THYM show a favorable association.

ACC, LIHC, and PAAD are the cancer types where ACTL6A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.395	0.751	<.001	74	view →
LIHC	OS	Median	All	0.609	0.766	<.001	71	view →
PAAD	OS	Median	All	0.283	0.519	<.001	67	view →
KICH	OS	Tertile	All	0.684	1.000	.003	65	view →
MESO	OS	Quartile	All	0.415	0.717	.002	60	view →
KIRP	DFS	Tertile	All	0.782	0.927	.002	55	view →
LGG	OS	Median	All	0.362	0.553	<.001	49	view →
SARC	OS	Tertile	All	0.388	0.653	<.001	44	view →
KIRC	DFS	Tertile	All	0.854	0.670	.001	34	view →
UCEC	DFS	Quartile	All	0.684	0.872	.002	16	view →
LUAD	OS	Quartile	All	0.198	0.465	.002	15	view →
ESCA	OS	Median	III,IV	0.433	0.665	.014	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

ACTL6A–ACC (DFS)

Open the ACC breakdown →